Immuno-Oncology

Opportunities in Immunotherapy

The POP BIO SNAP platform has the potential serve as a powerful platform for the development of immunotherapies.

Effective Anti-Tumor Treatment
• Nanograms of peptide reverse established and metastatic tumor growth in TC-1 tumor model
• Other cancer models show synergy with checkpoint blockade inhibition and other anti-tumor treatments

Find the Needle in the Haystack
• SNAP is ideal for multivalent immunization.
• Short peptide microlibraries with SNAP enables finding functional neoepitopes from candidate lists.

Make Self-Antigens Immunogenic
• Self-antigens typically are poorly immunogenic
• SNAP allows unbiased determination of mutated epitopes with enhanced function using a two-step microlibrary screening method

A New Approach for Short Peptide Cancer Vaccines

SNAP liposomes contain synthetic MPLA, QS-21 and Cobalt porphyrin phospholipid (CoPoP)

CoPoP enables liposomes to stably bind short MHC-I epitopes upon admixture.

Better delivery of epitopes and adjuvants to immune cells in draining lymph nodes

Induce higher frequency of antigen specific CD8+ T cells with > 10,000X lower peptide dosing

Instantly Harness the Power of Particle-Based Vaccines

Enhancing Antigen Display and Immune Response with SNAP Liposomes

SNAP liposomes contain Cobalt porphyrin phospholipid (CoPoP) and the lipid adjuvants synthetic MPLA and optionally QS-21

CoPoP enables rapid and biostable display of antigens on liposomes with simple mixing.

SNAP focuses the immune response on antigen of interest with protein-free scaffold technology

Our Clinical Pipeline

At POP Biotechnologies, we are leading the way in developing innovative immunotherapies. Our active Clinical Pipeline includes EuCorVac-19, our first vaccine currently in Phase III Trials. With our groundbreaking approach, we aim to revolutionize cancer treatment and improve patient outcomes.

Learn More Partner with Us

Selected Publications

Below is our carefully curated shortlist of more than 20 peer-reviewed publications that have been rigorously vetted by experts in the field and deemed to be of the highest quality.

Nature Chemistry, 2015
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens

Nature Nanotechnology, 2018
A malaria vaccine adjuvant based on recombinant antigen binding to liposomes

Advanced Materials, 2020
SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination

Vaccine, 2020
Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes

JITC, 2021
Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model

PNAS, 2021
A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge

Science Adv, 2021
Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice

BMC Medicine, 2022
Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine